BIIB, LMT, NOC, MA and MTD are five non-tech wide moat picks as durable advantages, defense demand, and digital payments growth position these stocks for resilient returns.

The local unit of US biotech major Biogen today announced that the UK’s Medicines and Healthcare Products Regulatory Agency ...

Spinal muscular atrophy (SMA) is a rare, genetic condition that, across all types, affects ~1,600 people in the UK.1 It can cause muscle weakness which gets worse over time, causing movement, ...

This high dose nusinersen regimen for spinal muscular atrophy includes 50 mg loading doses and 28mg maintenance doses.

Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial FDA approval for failed Alzheimer’s treatment, Aduhelm. The ...

Biogen BIIB0.89%increase; green up pointing triangle agreed to acquire Apellis Pharmaceuticals APLS 0.01%increase; green up pointing triangle for approximately $5.6 billion, expanding its portfolio in ...

Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 ⁠billion in cash, expanding its portfolio of rare-disease medicines, the companies said on Tuesday. The deal marks Biogen's push to ...

Biogen CEO sees strategic value in Apellis' kidney disease drug Deal to be financed with cash and borrowings Apellis shares more than double, Biogen stock fell nearly 5% Deal to add to adjusted profit ...

Please provide your email address to receive an email when new articles are posted on . The acquisition includes Syfovre for geographic atrophy and Empaveli for two rare kidney diseases and paroxysmal ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Biogen said Tuesday that ...

The MarketWatch News Department was not involved in the creation of this content. SCHAUMBURG, Ill., March 30, 2026 /PRNewswire/ -- Cure SMA, the leading nonprofit organization supporting those ...